Aziz Moqrich has been awarded the SATT IMPACT 2022 Prize for his team’s work on the TAFA4 protein


Dr Moqrich is Research Director at the IBDM laboratory (part of the CNRS, the French National Center for Scientific Research) and cofounder of Tafalgie Therapeutics. Th award recognizes the major discoveries he and his team have made, which have contributed to substantial advances in biology, and more specifically in pain research and innovative pain treatments.

SATT Sud-Est is the reference technology transfer office (TTO) for Aix-Marseille University and the CNRS unit of Dr. Moqrich. The SATT was instrumental in the valorization of the work culminating in the discovery of the therapeutic potential of the TAFA4 protein as a painkiller. This valorization involved several funding mechanisms and a series of administrative interventions with the CNRS and AMU to facilitate the launch of Tafalgie Therapeutics. In particular, SATT Sud-Est managed the TAFA4 patent and its first licensing agreement with Tafalgie Therapeutics, with SATT Sud-Est as one of the first investors.

During the awards ceremony, Aziz Moqrich presented his discovery of a new generation of non-opioid painkillers and the work of Tafalgie Therapeutics in this field.

Congratulations on this well-deserved honor! 

Visit our contact page